Artiva Biotherapeutics, Inc. Operating Cash Flow
Artiva Biotherapeutics, Inc. (ARTV) reported Operating Cash Flow of -$41.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$20.36M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$20.95M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$14.73M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$19.20M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$76.75M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$55.03M.
- Artiva Biotherapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$47.43M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$41.30M 10-Q · filed 2026-08-06 | -$56.03M derived: sum of 3 quarters · filed 2026-08-06 | -$75.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$20.95M 10-Q · filed 2026-05-08 | -$35.68M derived: sum of 2 quarters · filed 2026-05-08 | -$54.88M derived: sum of 3 quarters · filed 2026-05-08 | -$77.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$14.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$33.93M derived: sum of 2 quarters · filed 2026-03-10 | -$56.91M derived: sum of 3 quarters · filed 2026-08-06 | -$76.75M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$19.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$42.18M derived: sum of 2 quarters · filed 2026-08-06 | -$62.02M 10-Q · filed 2025-11-12 | -$76.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$22.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$42.82M 10-Q · filed 2026-08-06 | -$57.47M derived: sum of 3 quarters · filed 2026-08-06 | -$69.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$19.84M 10-Q · filed 2026-05-08 | -$34.49M derived: sum of 2 quarters · filed 2026-05-08 | -$46.10M derived: sum of 3 quarters · filed 2026-05-08 | -$59.79M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$14.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$26.26M derived: sum of 2 quarters · filed 2026-03-10 | -$39.95M derived: sum of 3 quarters · filed 2026-03-10 | -$55.03M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$11.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$25.30M derived: sum of 2 quarters · filed 2025-11-12 | -$40.38M 10-Q · filed 2025-11-12 | -$51.06M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$13.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$28.77M 10-Q · filed 2025-08-06 | -$39.45M derived: sum of 3 quarters · filed 2025-08-06 | -$50.19M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$15.09M 10-Q · filed 2025-05-08 | -$25.76M derived: sum of 2 quarters · filed 2025-05-08 | -$36.51M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$10.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$21.42M derived: sum of 2 quarters · filed 2025-03-24 | -$47.43M 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$10.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$36.76M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$26.01M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |